PATHOLOGICAL ASSESSMENTOF TUMOR RESPONSE IN A NEO-ADJUVANT THERAPY TREATED RESECTIONS FOR OSTEOSARCOMAS

Objective: To assess of the pathologic response of patients of osteosarcoma, after neoadjuvant chemotherapy. Study Design: Descriptive study. Place and Duration of Study: Shaukat Khanum Memorial Cancer Hospital & Research Centre, Lahore from Jan 2016 to Aug 2016. Material and Methods: A tota...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Syed Gardezi Saad Gardezi, Iftikhar Ali Rana, Asif Loya, Sajid Mushtaq, Noreen Akhter, Muhammad Tariq Mehmood
Formato: article
Lenguaje:EN
Publicado: Army Medical College Rawalpindi 2018
Materias:
R
Acceso en línea:https://doaj.org/article/a0f12aad198f44efb3dcd4dcc084e0c4
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
Descripción
Sumario:Objective: To assess of the pathologic response of patients of osteosarcoma, after neoadjuvant chemotherapy. Study Design: Descriptive study. Place and Duration of Study: Shaukat Khanum Memorial Cancer Hospital & Research Centre, Lahore from Jan 2016 to Aug 2016. Material and Methods: A total of 60 cases of osteosarcoma found suitable by inclusion criteria were included in this study. Demographic details such as name, sex and age were collected. All specimens were grossed and staged according to CAP guidelines. Tumor response was assessed by two pathologists and graded as good and poor response. Results: Sixty percent (n=36) of patients were between 7-18 years of age while 40% (n=24) of patients were between 19-45 years of age. Mean age was 17.65 years. A total of 58.33% (n=35) of patients were males and 41.67% (n=25) of patients were females. Thirty percent (n=18) of the patients had good response, while 70% (n=42) of patients had poor response to chemotherapy. Conclusion: We concluded that the assessment of pathologic response of osteosarcoma after neoadjuvant chemotherapy in terms of good response and poor response is a useful tool for the pathologist and the oncologist. It gives us useful information regarding patient’s response to neoadjuvant chemo radiotherapy that also helps in determining the further management and overall survival rate of the patient.